Abstract
Introduction

Fat depots around the heart and vasculature Definitions
Nearly all arteries as well as the heart are surrounded by fat depots. In the case of the human heart, two anatomically distinct fat depots cover approximately 80% of the heart, but the terminology used to describe these depots has been confusing. In this review, we will use the term EAT when referring to the adipose tissue located between the myocardium and the visceral pericardium, and pericardial fat when referring to the depot situated outside the visceral pericardium [3] . Others use the term paracardial fat for the adipose tissue located superficial to the pericardium and define pericardial fat as EAT plus paracardial adipose tissue [2] . PVAT refers to fat surrounding the blood vessels [7] .
Epicardial adipose tissue
Epicardial fat cells have the same embryologic origin as mesenteric and omental fat cells, and are derived from the splanchnopleuric mesoderm associated with the gut [3, 8, 9] . Epicardial fat cells have the same embryologic origin as mesenteric and omental fat cells, and are derived from the splanchnopleuric mesoderm associated with the gut [3, 8, 9] . EAT is commonly found at both ventricles in the atrioventricular and interventricular grooves extending to the apex, and along the coronary arteries [2, 4, 10, 11] . Post-mortem studies on individuals without clinical signs of CVD or diabetes mellitus and a body mass index in the upper normal range (25.2 Ϯ 3.6) showed that EAT constitutes approximately 20% of the total ventricular weight in the human heart [10] . The absolute amount of EAT is similar between the left and right ventricle [10] . However, when expressed per gram muscle tissue, the amount of fat covering the right ventricle is three times higher than for the left ventricle [10] . At the right ventricle, the adipose tissue is located over the lateral right ventricular wall followed by the right ventricular wall, with little present over the posterior wall [2, 4, 10, 11] . EAT and underlying myocardium share the same coronary blood supply and no fascia-like structure separates the two tissues [3, 11] . Based on these characteristics, EAT is considered to represent the true visceral fat depot of the heart.
Compared to other fat depots, the number of adipocytes per gram of EAT is higher, and their size is smaller [8, 12, 13] . Furthermore 
Association of epicardial fat with cardiovascular dysfunction
Visceral obesity is associated with an increased risk of CAD [51]. Interestingly, two population-based studies, the Multi-Ethnic Study of Atherosclerosis and the Framingham Heart study, identified the fat depots around the heart as independent risk predictors for CVD [52-54]. In these studies, the sum of epicardial and pericardial adipose tissue was determined. Because of its anatomic proximity to the adventitia and the major epicardial coronary arteries, it is highly likely that in particular alterations in EAT play an important role in the pathogenesis of CAD. Indeed, EAT thickness and volume was increased in patients with
Association of epicardial fat with the metabolic syndrome
The metabolic syndrome is a cluster of interrelated risk factors for CVD and T2DM [1] . Clinical markers for the metabolic syndrome [91, 92] . Expression of adiponectin, hepcidin, leptin and TNF-␣ in EAT was not significantly affected by cardiac surgery [92, 93] [94] . Furthermore, in a rat model of type 1 diabetes, secretion of adiponectin, leptin and visfatin from EAT was decreased, and secretion of IL-6 was slightly increased as compared to control rats [95] . [96] . [95] . Conditioned medium from subcutaneous human adipose tissue was found to inhibit contractile function in primary rat cardiomyocytes in vitro [97] . This cardio-depressant activity could be ascribed to FABP-4 [98] . Interestingly, FABP-4 expression is increased in EAT from patients with the metabolic syndrome [94] .
Several studies have evaluated alterations in adipokine expression in EAT in pathological states, like CAD and the metabolic syndrome, or following cardiac surgery (Table 2). In EAT from patients with CAD, the expression of protective factors, like adiponectin and adrenomedullin, was lower when compared to EAT from non-CAD patients [85-88]. Also intracoronary levels of adiponectin and adrenomedullin were lower in patients with CAD, and in the case of adiponectin, intracoronary levels were found to correlate with protein expression in EAT [88, 89]. Conversely, in CAD patients, EAT was found to express and secrete higher levels of the pro-inflammatory markers IL-1␤, IL-6, MCP-1 and TNF-␣, as compared to subcutaneous adipose tissue [15]. When CAD patients were compared with non-CAD patients, elevated expression of IL-6, leptin, sPLA2-IIA, resistin, TNF-␣ and visfatin have been reported [80, 86, 87, 90]. For sPLA2-IIA and resistin, also increases in secretion were found in patients with CAD [81, 90]. Elective cardiac surgery, which represents a major risk factor for post-operative development of insulin resistance, also induced the expression of proinflammatory mediators, like angiotensinogen, IL-6, MCP-1 and resistin
. Studies towards alterations in adipokine expression in EAT in relation to diabetes are limited. One study reports an increased expression of fatty acid binding protein 4 (FABP-4) in patients with the metabolic syndrome
To our knowledge, there are no reports describing alterations in adipokine expression in PVAT in pathological states in human beings. In mice, the effects of high-fat and high-fat high sucrose feeding, which may contribute to the induction of insulin resistance, were examined [19, 96]. Compared to mice fed a control diet, PVAT expression of adiponectin and FABP-4 was lower, and expression of leptin, MCP-1 and MIP-1␣ was higher in high-fat diet fed mice [19, 21]. Furthermore, high-fat diet feeding of mice led to increased release of MCP-1 from PVAT [21]. Also high-fat high-sucrose feeding in mice was found to lower adiponectin expression, whereas expression of MCP-1, TNF-␣ and PAI-1 was elevated in PVAT of these animals
Cross-talk between secretory products from EAT and the myocardium
It would be interesting to learn whether this increased expression is paralleled by enhanced secretion of FABP-4 from EAT.
One study describes an enhanced secretion of resistin from EAT in patients with CAD [90] . In the Framingham Offspring study, increased circulating levels of resistin were associated with incident heart failure [99] . Resistin may directly interfere with cardiac function. Overexpression of resistin was found to impair contractile function in rat cardiomyocytes [100] , and in primary mouse cardiomyocytes, resistin was found to reduce insulin-stimulated glucose uptake [101] .
Direct effects on cardiac function have also been reported for other adipokines, which include a cardioprotective action for adiponectin, and both cardioprotective and detrimental effects for leptin [102] [103] [104] [105] . Importantly, however, it has to be determined whether the changes in adipokine expression in EAT listed in Table 2 are paralleled by changes in secretion in pathological states. [83, 106, 107] . Furthermore, PVAT has 
Cross-talk between secretory products from PVAT and the vasculature
Vascular relaxation factors, pro-atherogenic adipokines and growth factors secreted from PVAT were found to directly regulate vascular function through paracrine and endocrine effects on the vascular wall. Initial studies on the interaction between PVAT and the vessel wall concentrated on the regulation of vasoreactivity, and ascribed both vasorelaxation and vasoconstriction to secretory products from PVAT
Vasorelaxation
An as yet unidentified factor, termed ADRF has been implicated in the induction of vasorelaxation in the aorta, as well as in smaller vessels in rats [83, 108] . It has been suggested that ADRF could be adiponectin. Indeed, adiponectin was found to act as a vasodilator, but studies on adiponectin-deficient mice showed that ADRF is not adiponectin [109] . Aortic rings from rats with and without PVAT and endothelium were used to study the mechanism of the anti-contractile action exerted by PVAT [110] . [110] . [111, 112] .
Vasoconstriction
Factors from PVAT can stimulate both relaxation and constriction depending on the localization of the vessel and the pathophysiological condition. Perivascular nerve activation by electric stimulation in rat aortic rings induces vasoconstriction, dependent on the presence of intact PVAT [107]. This response involves the production of superoxide by NAD(P)H oxdase, and was prevented by inhibitors of tyrosine kinase and the extracellular-signal regulated kinase pathway [107]. In dogs, it could be demonstrated that PVAT releases a vasocontractile factor that impairs coronary endothelial NO production via a protein kinase C-␤ mediated inhibitory phosphorylation of endothelial nitric oxide synthase
Vascular remodelling
Removal of PVAT in mice markedly enhanced neointima formation following endovascular injury [96] . This response was blunted by transplantation of subcutaneous adipose tissue [96] . These transplantation experiments provide the first evidence for a protective role of PVAT against neointima formation by regulatory effects on smooth muscle cell proliferation [96] [118] . In mice, increased neointima formation in high-fat high-sucrose fed mice was paralleled by a decreased expression of adiponectin [96, 119] , and induction of inflammatory markers like MCP-1, TNF-␣, IL-6 and PAI-1 in PVAT. Importantly, adiponectin-deficient mice display increased neo-intima formation when compared wild-type mice, and this effect could be reversed by local administration of adiponectin to the periadventitial area [96] . In line with this, adiponectin has been found to abrogate growth-factor induced smooth muscle cell proliferation and migration [120] 
